Search results
San Diego's Cue Health had the first FDA-approved home COVID-19 test. Now the agency says to throw...
U-T San Diego· 7 hours agoThe U.S. Food and Drug Administration told consumers Monday to throw out any at-home COVID-19 tests...
Why domestic U.S. production for lifesaving drugs is mandatory or innovation will die | Guest
Gannett via AOL· 6 days agoHealth care investors are showing renewed interest in biopharma following the long, uncertain...
FDA extends review of Ascendis Pharma's hypoparathyroidism drug By Investing.com
Investing.com· 24 hours agoAscendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company, has received notice from the U.S....
What will DEA rescheduling mean for cannabis in Alabama? Experts weigh in. - Birmingham Business...
The Business Journals· 18 hours agoLast month the U.S. Department of Drug Enforcement Administration announced plans to reclassify...
Zacks Industry Outlook Highlights Mettler-Toledo and Bruker
Zacks· 14 hours ago(MTD Quick QuoteMTD - Free Report) and Bruker (BRKR Quick QuoteBRKR - Free Report) . The Zacks Instruments - Scientific industry is benefiting from increasing healthcare spending ...
U.S. inflation eased last month in the first slowdown of 2024
Philly.com· 2 hours agoLed by lower food and auto prices, inflation in the United States cooled slightly last month after...
Catalysts of Change: Top Companies Driving Industry Evolution
USA Today· 22 minutes agoA catalyst is defined as “an agent that provokes or speeds significant change or action,” which is exactly what these top ten companies are doing. With a vision for a better tomorrow, they are ...
Inhibikase halts plans for public offering of securities By Investing.com
Investing.com· 3 hours ago(NASDAQ:IKT), a biopharmaceutical company focused on developing treatments for Parkinson's disease...
5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge
Bankrate via AOL· 7 days agoThe rise of GLP-1 drugs Drugs like Ozempic from Novo...receptors in the body, mimicking the effects...
InMed Pharmaceuticals (NASDAQ: INM) Releases Q3 Fiscal 2024 Financial Results
Digital Journal· 2 hours agoInMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, is reporting on ...